ABL Diagnostics Partners with Eurobio Scientific for Exclusive Distribution in France

ABL Diagnostics (Euronext Paris: ABLD), a leader in molecular diagnostics, has signed an exclusive agreement with Eurobio Scientific (Euronext Growth Paris: ALERS) for distributing its VELA product line in the French public hospital sector. This collaboration allows ABL to improve access to next-generation sequencing and viral genotyping solutions, prioritizing local service.

The agreement involves transferring certain customer responsibilities to Eurobio, while others remain under ABL's management. Eurobio has a long history with the VELA line, bolstering this strategic move. The partnership fits into ABL’s broader European expansion strategy, following recent similar announcements. VELA’s products focus on virology applications, such as HIV and HCV genotyping.

CEO Chalom Sayada emphasizes the agreement’s alignment with ABL's market growth goals, ensuring comprehensive yet tailored service.